Revenue
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Oramed Pharmaceuticals Inc. (ORMP)
Price$5.01Cached quote
Net income
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $0 | $1.3M | $2.7M | $2.7M | $2.7M | $2.7M | $2.4M | $2.5M | $641,000 | — | — | — | — | — | — | — | — |
| Gross profit | $13,000 | $0 | — | — | — | — | $2.6M | — | $2.3M | $151,000 | — | — | — | — | — | — | — | — |
| Gross margin | 0.65% | — | — | — | — | — | 96.67% | — | 92.39% | 23.56% | — | — | — | — | — | — | — | — |
| Research & development | $6.4M | $6.3M | $9.0M | $27.6M | $21.0M | $10.2M | $13.5M | $12.0M | $10.3M | $7.7M | $4.8M | $3.3M | $2.3M | $1.7M | $1.2M | — | — | — |
| Operating expenses | $15.1M | $12.8M | $17.1M | $43.3M | — | — | $17.2M | — | $13.0M | $10.2M | — | — | — | — | — | — | — | — |
| Operating income | −$15.1M | −$12.8M | −$15.8M | −$40.6M | −$24.2M | −$11.8M | −$14.6M | −$13.5M | −$10.8M | −$10.0M | −$7.4M | −$5.9M | $4.3M | −$2.9M | −$2.4M | — | — | — |
| Operating margin | −754.40% | — | −1,176.79% | −1,501.96% | −896.15% | −433.84% | −541.29% | −552.35% | −438.56% | −1,561.62% | — | — | — | — | — | — | — | — |
| EBITDA | −$15.0M | −$12.6M | −$15.6M | −$40.5M | −$24.1M | −$11.8M | −$14.6M | −$13.5M | −$10.8M | −$10.0M | −$7.4M | −$5.9M | $4.3M | −$2.9M | −$2.4M | — | — | — |
| EBITDA margin | −748.35% | — | −1,162.16% | −1,499.82% | −893.30% | −433.58% | −540.99% | −552.10% | −438.36% | −1,561.00% | — | — | — | — | — | — | — | — |
| Net income | $64.0M | −$19.1M | $5.1M | −$36.6M | −$23.0M | −$11.5M | −$14.4M | −$12.7M | −$10.5M | −$11.0M | −$7.2M | −$5.7M | $4.2M | −$3.3M | −$1.6M | −$3.0M | −$2.8M | −$2.8M |
| Net profit margin | 3,202.50% | — | 379.70% | −1,352.61% | −850.50% | −424.76% | −531.08% | −519.68% | −426.71% | −1,710.45% | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | $1.53 | -$0.48 | $0.14 | -$0.94 | $0.78 | $0.56 | $0.82 | $0.86 | $0.79 | $0.87 | $0.67 | $0.62 | $0.59 | $0.57 | -$0.02 | — | — | — |
| Diluted EPSper diluted share | $1.50 | -$0.48 | $0.14 | -$0.94 | $0.78 | $0.56 | $0.82 | $0.86 | $0.79 | $0.87 | $0.67 | $0.62 | $0.59 | $0.57 | -$0.02 | — | — | — |
Owners
Reported shareholders
9.22%of listed shares
MERCER GLOBAL ADVISORS INC /ADV3.81M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
MERCER GLOBAL ADVISORS INC /ADV | 9.22%3.81M shares |
KIDRON NADAV | ≈8.59%3.55M shares |
Aquamarine Financial (Cayman) Ltd | 6.08%2.51M shares |
Shapiro Benjamin | ≈4.90%2.02M shares |
Gem Investment Advisors, LLC | 4.84%2M shares |
BlackRock, Inc. | 3.89%1.61M shares |
Murchinson Ltd. | 3.12%1.29M shares |
Hexter Joshua | ≈2.81%1.16M shares |
Kidron Miriam | ≈2.74%1.13M shares |
BML Capital Management, LLC | 2.10%866.27K shares |
Gabay Avraham | ≈1.80%745.15K shares |
BOOTHBAY FUND MANAGEMENT, LLC | 1.40%578.64K shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.21%500.69K shares |
GOLDMAN SACHS GROUP INC | 0.61%253.29K shares |
STATE STREET CORP | 0.59%242.1K shares |
Rathbones Group PLC | 0.56%233.02K shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 0.56%229.88K shares |
DIMENSIONAL FUND ADVISORS LP | 0.49%202.61K shares |
NORTHERN TRUST CORP | 0.45%184.92K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.44%183.8K shares |
Percentages use 41.31M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data